Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

 
• By John Hodgson

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Arrows
Introducing Scrip 100 2018: analyzing the biopharma sector • Source: Shutterstock

More from Earnings

More from Business